Mankind Pharma Stock Plunges On Beige Block Deal, MSCI Inclusion Buzz

Mankind Pharma Ltd finds itself in the spotlight as reports suggest an imminent block deal involving a significant stake sale by Beige Ltd, an affiliate of ChrysCapital, a private equity firm. While Business Today awaits independent verification of this development, Nuvama Alternative & Quantitative Research has offered insights into the potential implications for Mankind Pharma's stock, hinting at a possible surge in value and inclusion in the prestigious MSCI Index in May 2024.

Mankind Pharma's shares declined by 1.40% to Rs 2184 on BSE and 1.33% to Rs 2133.40 on NSE.

The core analysis by Nuvama revolves around the assumption that if Beige Ltd. proceeds with shedding its 2.90 percent stake in Mankind Pharma through block deals, the stock could meet the criteria for MSCI inclusion during the May 24 review. This is contingent upon the timely disclosure of revised shareholding for the March quarter by April 16, 2024. Nuvama estimates that with the float anticipated to rise to 25 percent, the stock would likely surpass the necessary threshold for inclusion, potentially exceeding the Rs 1,850 mark.

Furthermore, Nuvama predicts a substantial inflow of approximately $156 million, equivalent to 5 million shares, with an anticipated impact over 15 days. This influx, coupled with limited float availability, fuels Nuvama's confidence in Mankind Pharma's stock performance, with projections pointing towards an expedited climb to surpass the Rs 2,500 level in the short term. As of the latest market close, the stock stood at Rs 2,208.20, reflecting a notable 3.46 percent increase.

In addition to MSCI inclusion prospects, Mankind Pharma's membership in the FTSE Index further enhances its market positioning. Nuvama's calculations indicate an expected weight-up inflow of approximately 10 million shares, underscoring the company's growing significance in global indices.

Abhilash Pagaria, Head of Nuvama Alternative and Quantitative Research, emphasises the imminent weight-up phenomenon, anticipating a surge in the coming days. These projections reflect broader market sentiments regarding Mankind Pharma's growth potential and its increasing prominence in global investment portfolios.

Beyond the financial intricacies, Mankind Pharma's diverse portfolio encompasses acute and chronic therapeutic areas, spanning from anti-infectives to cardiovascular and respiratory medications. Additionally, the company's foray into consumer healthcare encompasses a wide array of categories, including condoms, pregnancy detection, emergency contraceptives, and vitamin supplements, bolstered by a portfolio of category-leading brands.

Mankind Pharma's robust infrastructure, boasting 25 manufacturing facilities in India, underscores its commitment to product innovation and quality. These facilities produce a wide range of dosage forms, including tablets, capsules, syrups, vials, and ampoules, reflecting the company's versatility and capacity to meet market demands. Supported by four dedicated research and development facilities and a team of over 600 scientists, Mankind Pharma maintains a consistent track record of innovation and excellence.

The company's recent financial performance underscores its resilience and growth trajectory, with a staggering 55.5 percent year-on-year increase in profit and a commendable 24.7 percent rise in sales for the December quarter. Furthermore, the EBITDA grew by 39.1 percent to Rs 611 crore, accompanied by a notable expansion of the EBITDA margin by 240 basis points to 23.40 percent for the quarter.

Mankind Pharma's potential for inclusion in global indices and its robust financial performance signal a promising outlook for investors. With anticipated block deals, market inflows, and a strategic focus on innovation and expansion, the company is poised for significant growth, reaffirming its position as a key player in the pharmaceutical industry's landscape.